BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Update

BrainsWay Ltd. (NASDAQ:BWAY - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 104,000 shares, a decrease of 16.9% from the March 15th total of 125,100 shares. Based on an average daily volume of 64,000 shares, the short-interest ratio is presently 1.6 days. Currently, 0.7% of the company's shares are sold short.

Institutional Trading of BrainsWay

Large investors have recently made changes to their positions in the stock. Two Sigma Investments LP lifted its holdings in BrainsWay by 2.0% during the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company's stock valued at $875,000 after buying an additional 1,786 shares in the last quarter. Rhumbline Advisers raised its stake in shares of BrainsWay by 10.8% during the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock valued at $207,000 after acquiring an additional 2,144 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of BrainsWay by 14.6% during the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company's stock valued at $181,000 after acquiring an additional 2,446 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of BrainsWay in the fourth quarter valued at approximately $44,000. Finally, GAMMA Investing LLC grew its stake in BrainsWay by 720.7% in the first quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock worth $89,000 after purchasing an additional 8,216 shares in the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and set a $16.00 target price on shares of BrainsWay in a research report on Wednesday, March 12th.

BrainsWay Stock Up 3.0 %

BWAY traded up $0.26 during trading hours on Thursday, reaching $9.05. 8,984 shares of the company's stock traded hands, compared to its average volume of 72,437. The firm has a 50-day moving average price of $9.44 and a 200 day moving average price of $9.78. The firm has a market capitalization of $170.76 million, a PE ratio of 90.51 and a beta of 1.17. BrainsWay has a 52-week low of $4.72 and a 52-week high of $11.79.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.